PURPOSE: Aim was to compare the functional status in long-term breast cancer survivors related to age at diagnosis and to asses the effects of adjuvant therapy on health-related quality of life (HRQoL). PATIENTS AND METHODS: Data were obtained from 370 patients after breast conserving therapy (BCT) at follow-up (F/U) visit. The self-administered EORTC QoL questionnaire (C30) and the breast module (QLQ-BR23) measuring global health, global QoL, physical, role, emotional, cognitive and social functioning, body image, sexual function, future perspective and arm/breast symptoms were used. Patients were grouped according to F/U (12 years, 7 years), age at therapy (< 50 years, 50-65 years, >65 years) and adjuvant treatment (none, chemotherapy, hormone replacement therapy). RESULTS: The global HRQoL was increased in patients with longer F/U (p < 0.01). Physical functioning, role functioning and sexual functioning were decreased in patients being older at therapy (> 65 years, p < 0.01). Increased arm symptoms were noticed in older women at longer follow-up. Younger women at therapy complained financial difficulties at follow-up (p < 0.006). Adjuvant chemotherapy and hormone replacement therapy did not affect physical and mental functioning. CONCLUSION: Women of different age treated with BCT for breast cancer should be considered at a different risk for HRQoL disturbance at long term F/U in both, physical and psychological dimensions. In clinical practice, specific identification of those women with negative impact of diagnosis and treatment on long term HRQoL would help for targeted interventions. In clinical studies focusing on HRQoL, the compared groups need to be age-adjusted.
PURPOSE: Aim was to compare the functional status in long-term breast cancer survivors related to age at diagnosis and to asses the effects of adjuvant therapy on health-related quality of life (HRQoL). PATIENTS AND METHODS: Data were obtained from 370 patients after breast conserving therapy (BCT) at follow-up (F/U) visit. The self-administered EORTC QoL questionnaire (C30) and the breast module (QLQ-BR23) measuring global health, global QoL, physical, role, emotional, cognitive and social functioning, body image, sexual function, future perspective and arm/breast symptoms were used. Patients were grouped according to F/U (12 years, 7 years), age at therapy (< 50 years, 50-65 years, >65 years) and adjuvant treatment (none, chemotherapy, hormone replacement therapy). RESULTS: The global HRQoL was increased in patients with longer F/U (p < 0.01). Physical functioning, role functioning and sexual functioning were decreased in patients being older at therapy (> 65 years, p < 0.01). Increased arm symptoms were noticed in older women at longer follow-up. Younger women at therapy complained financial difficulties at follow-up (p < 0.006). Adjuvant chemotherapy and hormone replacement therapy did not affect physical and mental functioning. CONCLUSION:Women of different age treated with BCT for breast cancer should be considered at a different risk for HRQoL disturbance at long term F/U in both, physical and psychological dimensions. In clinical practice, specific identification of those women with negative impact of diagnosis and treatment on long term HRQoL would help for targeted interventions. In clinical studies focusing on HRQoL, the compared groups need to be age-adjusted.
Authors: Juan Ignacio Arraras; Ana Manterola; Miguel Angel Domínguez; Fernando Arias; Elena Villafranca; Pilar Romero; Enrique Martínez; José Juan Illarramendi; Esteban Salgado Journal: Clin Transl Oncol Date: 2008-08 Impact factor: 3.405
Authors: Olivia S Fu; Katherine D Crew; Judith S Jacobson; Heather Greenlee; Gary Yu; Julie Campbell; Yvette Ortiz; Dawn L Hershman Journal: J Cancer Surviv Date: 2009-10-27 Impact factor: 4.442
Authors: Mauriceia C L de Medeiros; Daniela F Veiga; Miguel Sabino Neto; Luis E F Abla; Yara Juliano; Lydia M Ferreira Journal: Clinics (Sao Paulo) Date: 2010 Impact factor: 2.365
Authors: Anna P B M Braeken; Lilian Lechner; Francis C J M van Gils; Ruud M A Houben; Daniëlle Eekers; Ton Ambergen; Gertrudis I J M Kempen Journal: BMC Cancer Date: 2009-06-09 Impact factor: 4.430
Authors: Alberto Carmona-Bayonas; Caterina Calderón; Raquel Hernández; Ana Fernández Montes; Beatriz Castelo; Laura Ciria-Suarez; Mónica Antoñanzas; Jacobo Rogado; Vilma Pacheco-Barcia; Elena Asensio Martínez; Alejandra Ivars; Francisco Ayala de la Peña; Paula Jimenez-Fonseca Journal: NPJ Breast Cancer Date: 2021-07-13